Arena Pharmaceuticals, Inc. (ARNA) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Arena Pharma (ARNA) Posts Modest BELVIQ Sales, BMO Capital Notes
May 13, 2014 8:02 AM EDTBMO Capital analyst Jim Birchenough, M.D. reiterated a Market Perform rating on Arena Pharma (NASDAQ: ARNA) following a Q1 net loss of $0.12 versus the consensus of a $0.10 loss, and an ending cash balance of $256.5 million.
The analyst also highlights revenues were $6.8 million, including $2.9 million in net product sales of weight loss drug BELVIQ, of which $2.7 million... More
